A Review Of IMB-808
In the multiday, many-dose arm, baseline microbiota was equivalent involving subjects that acquired ibezapolstat compared with vancomycin. At Day 10 of dosing, differential abundance analysis and β-variety demonstrated a definite difference between the microbiome in subjects specified vancomycin in comparison with either dose of ibezapolstat (Addi